Business

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma

articleSichuan Biokin Pharmaceutical Co., Ltd. Class ANovember 23, 20253/news/announcement-on-voluntary-disclosure-of-the-acceptance-of-the-new-drug-application-for-iza-bren-an-egfrher3-bispecific-antibody-drug-conjugate-for-the-treatment-of-locally-advanced-or-metastatic-nasopharyngeal-carcinoma
Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific Antibody-Drug Conjugate) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal CarcinomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A